PERPHENAZINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Perphenazine is a typical antipsychotic that exerts its effects by blocking postsynaptic dopamine D2 receptors in the brain, particularly in the mesolimbic pathway. It also has antagonistic activity at alpha-adrenergic, histaminergic, and muscarinic receptors.
| Metabolism | Primarily hepatic via CYP2D6, with minor contributions from CYP3A4 and CYP1A2. |
| Excretion | Perphenazine is extensively metabolized in the liver, primarily via CYP2D6, and eliminated predominantly as metabolites in urine (approximately 70%) and feces (about 30%). Less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life of perphenazine is approximately 8–12 hours in adults with normal hepatic function. This supports twice-daily dosing for maintenance therapy. In elderly patients or those with hepatic impairment, half-life may be prolonged. |
| Protein binding | Perphenazine is approximately 90–95% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The volume of distribution (Vd) is approximately 10–20 L/kg, indicating extensive tissue distribution and high lipophilicity. This large Vd explains its long elimination half-life and accumulation in brain tissue. |
| Bioavailability | Oral bioavailability is approximately 40–50% due to extensive first-pass metabolism. Intramuscular bioavailability is near 100%; intravenous administration yields complete bioavailability. |
| Onset of Action | Oral: 30–60 minutes; intramuscular (IM): 10–30 minutes; intravenous (IV): 5–10 minutes. The onset of antipsychotic effect may require days to weeks. |
| Duration of Action | Duration of effect for a single oral dose is approximately 6 hours for acute effects (e.g., antiemetic action), but antipsychotic effects are sustained over 24 hours with chronic dosing. The IM route provides a longer duration (6–12 hours) due to slower absorption. |
| Molecular Weight | 403.97 |
Oral: 4-16 mg 2-4 times daily; maximum 64 mg/day. Intramuscular: 5-10 mg every 6 hours; maximum 30 mg/day. Intravenous: 1-5 mg slow IV every 6 hours; maximum 10 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in severe renal dysfunction. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; reduce dose by 75% or avoid. |
| Pediatric use | Children (≥12 years): 2-4 mg orally 3-4 times daily; maximum 32 mg/day. Intramuscular: 2-5 mg every 6 hours; maximum 15 mg/day. Children (6-12 years): Not recommended due to limited data. |
| Geriatric use | Initial oral dose: 2-4 mg 2-3 times daily; increase slowly. Maximum 32 mg/day. Use lowest effective dose due to increased sensitivity to extrapyramidal effects and orthostatic hypotension. |
| 1st trimester | Perphenazine crosses the placenta. There are limited human data; animal studies show embryotoxicity at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | Use cautiously; monitor for maternal extrapyramidal symptoms and neonatal effects. Consider lower doses if used. |
| 3rd trimester | May cause neonatal extrapyramidal symptoms, withdrawal, or sedation after delivery. Use near term only if clearly needed. |
Clinical note
CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.
| Placental transfer | Perphenazine crosses the placenta. It is lipophilic and has a moderate molecular weight, enabling transfer. |
| Breastfeeding | Perphenazine is excreted into breast milk in low levels. In general, antipsychotics with lower milk excretion are preferred. Monitor infant for drowsiness, irritability, and abnormal movements. The American Academy of Pediatrics considers perphenazine compatible with breastfeeding, but caution is advised. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
| Common Effects | Extrapyramidal symptoms |
| Serious Effects |
Comatose statesCNS depression due to alcohol, barbiturates, or opioidsKnown hypersensitivity to perphenazine or phenothiazinesBone marrow suppressionSubcortical brain damage with hypothalamic dysfunction
| Precautions | Risk of tardive dyskinesia with prolonged use, Neuroleptic malignant syndrome (NMS), QT prolongation and arrhythmias, Leukopenia/neutropenia/agranulocytosis, Seizure threshold lowering, Hyperprolactinemia, Drowsiness and impaired judgment, Orthostatic hypotension, Anticholinergic effects (constipation, dry mouth, blurred vision) |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Perphenazine is a phenothiazine antipsychotic. First trimester: Human data limited; case reports suggest possible minor malformations but no clear pattern. Second and third trimesters: Exposure may cause extrapyramidal symptoms (EPS) and/or withdrawal in the neonate, including agitation, hypertonia, hypotonia, tremor, somnolence, and feeding difficulty. Overall risk not clearly established. FDA Pregnancy Category C. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of EPS or tardive dyskinesia. Monitor fetal growth if used chronically. In neonates, monitor for EPS, sedation, and withdrawal symptoms for 48-72 hours after delivery. Consider therapeutic drug monitoring if available. |
| Fertility Effects | May cause hyperprolactinemia, potentially leading to menstrual irregularities, galactorrhea, and impaired fertility. Reversible upon dose reduction or discontinuation. No known direct effect on sperm or oocyte quality. |
| Avoid alcohol. Limit caffeine intake as it may exacerbate anxiety or insomnia. Grapefruit juice may increase perphenazine levels (CYP3A4 inhibition); avoid large quantities. |
| Clinical Pearls | Perphenazine is a typical antipsychotic with high potency and significant extrapyramidal symptom (EPS) risk. Use lowest effective dose for short term. Monitor for tardive dyskinesia, neuroleptic malignant syndrome, and QT prolongation. Avoid in elderly with dementia due to increased mortality. Caution in hepatic impairment. May lower seizure threshold. Antiemetic properties can mask toxicity of other drugs or conditions. Coadministration with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) requires dose reduction. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · You may experience drowsiness, dizziness, or blurred vision. Avoid driving or operating machinery until you know how this medication affects you. · Report any involuntary muscle movements, stiffness, fever, confusion, or rapid heartbeat to your doctor immediately. · Avoid alcohol and other central nervous system depressants. · Get up slowly from a seated or lying position to minimize dizziness. · Stay hydrated and avoid overheating; may impair body temperature regulation. · Notify all healthcare providers you are taking this medication. · Use effective contraception if of childbearing potential; discuss risks and benefits during pregnancy. |